Feature|Articles|May 14, 2024
- Pharmaceutical Executive: May 2024
- Volume 44
- Issue 5
Pharmaceutical Executive: May 2024 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive May 2024 issue in an interactive PDF format.
Advertisement
Articles in this issue
about 2 years ago
'Patients are Waiting'about 2 years ago
Today’s New Messaging Mix: The State of Pharma Marketing in 2024about 2 years ago
Patient Treatment & Travel: The Need for Stepped-Up Supportabout 2 years ago
A Biosimilars Roadmap: Understanding Payer Perceptionsabout 2 years ago
Avoiding the Digital Age is Hurting Research Effortsabout 2 years ago
Biotech’s Road to Recovery Takes a Wobbly Turnabout 2 years ago
Yvonne Greenstreet: Answering the Callabout 2 years ago
Lessons Learned on the Art and Science of Product CommercializationAdvertisement
Advertisement
Advertisement
Trending on PharmExec
1
Deepening Ties: Why China is Becoming Big Pharma's Most Essential R&D Partner
2
GSK Enters $10.6 Billion Agreement to Acquire Nuvalent Inc.
3
Pharma Funding Roundup: City Therapeutics Closes $99.5 Million Series B, Eloxx Pharmaceuticals Announces Pricing of $66 Million Public Offering
4
Pharmaceutical Executive Daily: GSK Acquires Nuvalent for $10.6 Billion
5